Literature DB >> 22790706

Merely miR210 in mesenchymal stem cells--one size fits all.

Friedrich C Luft1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22790706     DOI： 10.1007/s00109-012-0933-9

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN： 0946-2716            Impact factor:   4.599


× No keyword cloud information.
  9 in total

Review 1.  Mesenchymal stromal cells: new directions.

Authors:  Armand Keating
Journal:  Cell Stem Cell       Date:  2012-06-14       Impact factor: 24.633

2.  Stem cell-based delivery of Hypoxamir-210 to the infarcted heart: implications on stem cell survival and preservation of infarcted heart function.

Authors:  Ha Won Kim; Shujia Jiang; Muhammad Ashraf; Khawaja Husnain Haider
Journal:  J Mol Med (Berl)       Date:  2012-05-31       Impact factor: 4.599

Review 3.  MiR-210--micromanager of the hypoxia pathway.

Authors:  Xin Huang; Quynh-Thu Le; Amato J Giaccia
Journal:  Trends Mol Med       Date:  2010-04-29       Impact factor: 11.951

4.  Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.

Authors:  Jianming Tan; Weizhen Wu; Xiumin Xu; Lianming Liao; Feng Zheng; Shari Messinger; Xinhui Sun; Jin Chen; Shunliang Yang; Jinquan Cai; Xia Gao; Antonello Pileggi; Camillo Ricordi
Journal:  JAMA       Date:  2012-03-21       Impact factor: 56.272

Review 5.  Role of microRNAs in the reperfused myocardium towards post-infarct remodelling.

Authors:  Hongyan Zhu; Guo-Chang Fan
Journal:  Cardiovasc Res       Date:  2011-10-28       Impact factor: 10.787

6.  Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial.

Authors:  Roberto Bolli; Atul R Chugh; Domenico D'Amario; John H Loughran; Marcus F Stoddard; Sohail Ikram; Garth M Beache; Stephen G Wagner; Annarosa Leri; Toru Hosoda; Fumihiro Sanada; Julius B Elmore; Polina Goichberg; Donato Cappetta; Naresh K Solankhi; Ibrahim Fahsah; D Gregg Rokosh; Mark S Slaughter; Jan Kajstura; Piero Anversa
Journal:  Lancet       Date:  2011-11-14       Impact factor: 79.321

Review 7.  miR-210: the master hypoxamir.

Authors:  Yuk C Chan; Jaideep Banerjee; Sang Yong Choi; Chandan K Sen
Journal:  Microcirculation       Date:  2012-04       Impact factor: 2.628

8.  A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.

Authors:  Joshua M Hare; Jay H Traverse; Timothy D Henry; Nabil Dib; Robert K Strumpf; Steven P Schulman; Gary Gerstenblith; Anthony N DeMaria; Ali E Denktas; Roger S Gammon; James B Hermiller; Mark A Reisman; Gary L Schaer; Warren Sherman
Journal:  J Am Coll Cardiol       Date:  2009-12-08       Impact factor: 24.094

9.  Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial.

Authors:  Raj R Makkar; Rachel R Smith; Ke Cheng; Konstantinos Malliaras; Louise Ej Thomson; Daniel Berman; Lawrence Sc Czer; Linda Marbán; Adam Mendizabal; Peter V Johnston; Stuart D Russell; Karl H Schuleri; Albert C Lardo; Gary Gerstenblith; Eduardo Marbán
Journal:  Lancet       Date:  2012-02-14       Impact factor: 79.321
  9 in total
  1 in total

1.  A positive feedback loop promotes HIF-1α stability through miR-210-mediated suppression of RUNX3 in paraquat-induced EMT.

Authors:  Yong Zhu; Jinfeng Wang; Xiaoxiao Meng; Hui Xie; Jiuting Tan; Xinkun Guo; Peng Han; Ruilan Wang
Journal:  J Cell Mol Med       Date:  2017-07-12       Impact factor: 5.310
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.